EP Patent

EP3638240A2 — Methods to treat opioid use disorder

Assigned to Indivior UK Ltd · Expires 2020-04-22 · 6y expired

What this patent protects

The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

USPTO Abstract

The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

Drugs covered by this patent

Patent Metadata

Patent number
EP3638240A2
Jurisdiction
EP
Classification
—
Expires
2020-04-22
Drug substance claim
No
Drug product claim
No
Assignee
Indivior UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.